Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Liabilities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Total Liabilities for 11 consecutive years, with $27.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 42.71% year-over-year to $27.9 million, compared with a TTM value of $27.9 million through Sep 2025, up 42.71%, and an annual FY2024 reading of $28.1 million, up 6.77% over the prior year.
  • Total Liabilities was $27.9 million for Q3 2025 at Dare Bioscience, up from $25.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $32.7 million in Q4 2022 and bottomed at $7.1 million in Q2 2021.
  • Average Total Liabilities over 5 years is $22.2 million, with a median of $24.0 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 159.39% in 2022, then dropped 28.52% in 2024.
  • Year by year, Total Liabilities stood at $17.1 million in 2021, then skyrocketed by 91.84% to $32.7 million in 2022, then dropped by 19.52% to $26.3 million in 2023, then rose by 6.77% to $28.1 million in 2024, then dropped by 0.79% to $27.9 million in 2025.
  • Business Quant data shows Total Liabilities for DARE at $27.9 million in Q3 2025, $25.7 million in Q2 2025, and $28.2 million in Q1 2025.